The Association of Ultra-Orphan and Orphans Drugs Manufacturers (Aelmhu) has launched a complaint due to the considerable reduction in approvals for reimbursement for these drugs by the autonomous regions. The problem is that the autonomous regions themselves also complain sometimes that the Health Ministry approved high-priced drugs, increasing the strain on regional finances.
Valencia, Murcia, Aragon, Castilla-La Mancha, Catalonia and Extremadura will be “unlikely” or “very unlikely” to meet the deficit in 2016. The impact this will have on the regional public spending, and health can be dramatic.
Click here to find out more.